Next Article in Journal
Duodenal Dual-Wavelength Photobiomodulation Improves Hyperglycemia and Hepatic Parameters with Alteration of Gut Microbiome in Type 2 Diabetes Animal Model
Next Article in Special Issue
Evaluation of Possible Neobavaisoflavone Chemosensitizing Properties towards Doxorubicin and Etoposide in SW1783 Anaplastic Astrocytoma Cells
Previous Article in Journal
Inhibition of Glucose Uptake Blocks Proliferation but Not Cytotoxic Activity of NK Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B

1
Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy
2
Department of Onco-Hematology, Gene and Cell Therapy, Bambino Gesù Children’s Hospital-IRCCS, 00146 Rome, Italy
3
Department of Chemistry, University of South Florida, Tampa, FL 33620, USA
4
Institute of Translational Pharmacology, National Research Council, CNR, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Cells 2022, 11(21), 3486; https://doi.org/10.3390/cells11213486
Submission received: 16 September 2022 / Revised: 31 October 2022 / Accepted: 2 November 2022 / Published: 3 November 2022
(This article belongs to the Special Issue Natural Products in the Treatment of Cancer)

Abstract

Human topoisomerase 1B regulates the topological state of supercoiled DNA enabling all fundamental cell processes. This enzyme, which is the unique molecular target of the natural anticancer compound camptothecin, acts by nicking one DNA strand and forming a transient protein–DNA covalent complex. The interaction of human topoisomerase 1B and dimethylmyricacene, a compound prepared semisynthetically from myricanol extracted from Myrica cerifera root bark, was investigated using enzymatic activity assays and molecular docking procedures. Dimethylmyricacene was shown to inhibit both the cleavage and the religation steps of the enzymatic reaction, and cell viability of A-253, FaDu, MCF-7, HeLa and HCT-116 tumor cell lines.
Keywords: human topoisomerase 1B; dimethylmyricacene; natural compound inhibition human topoisomerase 1B; dimethylmyricacene; natural compound inhibition

Share and Cite

MDPI and ACS Style

Ottaviani, A.; Iacovelli, F.; Welsch, J.; Morozzo della Rocca, B.; Desideri, A.; Falconi, M.; Calcul, L.; Baker, B.J.; Fiorani, P. Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B. Cells 2022, 11, 3486. https://doi.org/10.3390/cells11213486

AMA Style

Ottaviani A, Iacovelli F, Welsch J, Morozzo della Rocca B, Desideri A, Falconi M, Calcul L, Baker BJ, Fiorani P. Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B. Cells. 2022; 11(21):3486. https://doi.org/10.3390/cells11213486

Chicago/Turabian Style

Ottaviani, Alessio, Federico Iacovelli, Joshua Welsch, Blasco Morozzo della Rocca, Alessandro Desideri, Mattia Falconi, Laurent Calcul, Bill J. Baker, and Paola Fiorani. 2022. "Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B" Cells 11, no. 21: 3486. https://doi.org/10.3390/cells11213486

APA Style

Ottaviani, A., Iacovelli, F., Welsch, J., Morozzo della Rocca, B., Desideri, A., Falconi, M., Calcul, L., Baker, B. J., & Fiorani, P. (2022). Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B. Cells, 11(21), 3486. https://doi.org/10.3390/cells11213486

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop